On 30 October 2018, the Brazilian National Institute of Industrial Property (INPI) in order to reduce its current backlog published Rule 227/2018, regulating for the analysis of patents using the results of searches in other national or regional patent offices.

In the latest chapter regarding the pilot project of shared priority examination, the Patent Prosecution Highway ("PPH"), the Brazilian Patent and Trademark Office ("BPTO") published in the Official Industrial Property Bulletin No. 2485, dated August 21, 2018, Resolution No. 223, which sets forth the regulation of the program signed with the Danish Patent and Trademark Office - DKPTO.

Often clients, unaccustomed to Brazil, fret about the wrong problem, such as the backlog. Alternatively, they try to solve a problem with the wrong solution, like drafting a standard licensing agreement...

On 30 October 2018, the Brazilian National Institute of Industrial Property (INPI) in order to reduce its current backlog published Rule 227/2018, regulating for the analysis of patents using the results of searches in other national or regional patent offices.

On April 20, 2018, Brazilian "mailbox" patent PI9507594-1 by Alexion Pharmaceutical Inc. protecting the drug Soliris® (eculizumab) received an unfavorable ruling by the Brazilian Superior Court of Justice regarding its term of protection.

In the latest chapter regarding the pilot project of shared priority examination, the Patent Prosecution Highway ("PPH"), the Brazilian Patent and Trademark Office ("BPTO") published in the Official Industrial Property Bulletin No. 2485, dated August 21, 2018, Resolution No. 223, which sets forth the regulation of the program signed with the Danish Patent and Trademark Office - DKPTO.

On 30 October 2018, the Brazilian National Institute of Industrial Property (INPI) in order to reduce its current backlog published Rule 227/2018, regulating for the analysis of patents using the results of searches in other national or regional patent offices.

On April 20, 2018, Brazilian "mailbox" patent PI9507594-1 by Alexion Pharmaceutical Inc. protecting the drug Soliris® (eculizumab) received an unfavorable ruling by the Brazilian Superior Court of Justice regarding its term of protection.

The relevant authority is the Brazilian Patent and Trademark Office ("BPTO"), also referred to as the National Institute for Industrial Property (Instituto Nacional da Propriedade Industrial – "INPI", in Portuguese).

Further to our newsletter 12/16, please be informed that the Brazilian Patent Office issued on 1.March 2017 the Resolution No. 179 revoking Resolution 174, which was addressed in said previous newsletter.